\-\ Texto\\:\\ \ \(0\)\
\-\ on\\ examination\\ the\\ patient\\â\\€\\™s\\ lungs\\ were\\ clear\\ to\\ auscultation\\.\\ \\ her\\ heart\\ rate\\ was\\ regular\\ without\\ murmurs\\,\\ gallops\\ or\\ rubs\\.\\ \\ neurologic\\ examination\\ was\\ normal\\.\\ \\ her\\ room\\ air\\ resting\\ sao2\\ was\\ 99\\%\\ which\\ quickly\\ fell\\ to\\ 93\\%\\ with\\ ambulation\\.\\ \\ following\\ imaging\\,\\ bronchioaveolar\\ lavage\\ was\\ conducted\\ revealing\\ cryptococcus\\ neoformans\\ on\\ fluid\\ culture\\.\\ \\ cell\\ count\\ 1\\ revealed\\ rbc\\ 386\\,\\ wbc\\ 133\\,\\ neutrophils\\ 9\\,\\ lymphocytes\\ 24\\,\\ and\\ macrophages\\ 67\\.\\ \\ cell\\ count\\ 2\\ revealed\\ rbc\\ 363\\,\\ wbc\\ 199\\,\\ neutrophils\\ 41\\,\\ lymphocytes\\ 24\\,\\ macrophages\\ 33\\,\\ and\\ eosinophils\\ 2\\.\\ culture\\ was\\ negative\\ to\\ all\\ else\\ including\\ aerobic\\ cultures\\,\\ acid\\ fast\\ bacilli\\,\\ and\\ fungal\\ smears\\.\\ \\ subsequent\\ serum\\ labs\\ revealed\\ a\\ negative\\ anca\\,\\ ige\\ 64\\,\\ ldh\\ 586\\,\\ eosinophils\\ 0\\,\\ and\\ negative\\ hiv\\.\\ \\ serum\\ cryptococcal\\ antigen\\ testing\\ was\\ also\\ negative\\.\ \(0\)\
\-\ due\\ to\\ the\\ symptomatic\\ nature\\ of\\ her\\ disease\\,\\ treatment\\ was\\ begun\\ with\\ fluconazol\\ 300\\ mg\\ by\\ mouth\\ daily\\ for\\ 6\\ months\\.\\ \\ her\\ check\\-up\\ 1\\ month\\ later\\ revealed\\ markedly\\ decreased\\ nodular\\ infiltrates\\ on\\ both\\ chest\\ x\\-ray\\ and\\ ct\\.\\ \\ the\\ patient\\ also\\ reported\\ resolution\\ of\\ her\\ cough\\ and\\ overall\\ malaise\\.\ \(0\)\
\-\ chest\\ x\\-ray\\ demonstrated\\ rounded\\ lobular\\ nodules\\ in\\ the\\ left\\ lower\\ lobe\\.\\ \\ ct\\ pulmonary\\ angiogram\\ revealed\\ multiple\\ enhancing\\ left\\ lower\\ lobe\\ masses\\,\\ some\\ with\\ cavitation\\.\ \(0\)\
\-\ cryptococcal\\ pneumonia\ \(0\)\
\-\ 1\\)\\ malignancy\ \(0\)\
\-\ metastatic\\ disease\\:\\ testicular\\,\\ ovarian\\,\\ renal\\,\\ breast\\,\\ melanoma\\ and\\ sarcoma\ \(0\)\
\-\ lymphoma\ \(373\)\
\-\ benign\\:\\ hamartomas\\,\\ papillomatosis\\,\\ bronchogenic\\ cysts\\,\\ benign\\ metastasizing\\ leiomyomatosis\\ \ \(0\)\
\-\ 2\\)\\ infectious\ \(0\)\
\-\ multiple\\ abscesses\ \(1\)\
\-\ septic\\ emboli\ \(22\)\
\-\ granulomatous\\ infections\ \(1\)\
\-\ viral\\:\\ varicella\\,\\ measles\ \(0\)\
\-\ parasitic\\:\\ paragonimus\\ westermani\\ \ \(0\)\
\-\ 3\\)\\ inflammatory\ \(0\)\
\-\ wegener\\â\\€\\™s\\ granulomatosis\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ rheumatoid\\ nodules\ \(0\)\
\-\ a\\ 53\\-year\\-old\\ woman\\ presents\\ to\\ the\\ ed\\ with\\ a\\ three\\ month\\ history\\ of\\ a\\ chronic\\ dry\\ cough\\,\\ malaise\\,\\ and\\ increasing\\ dyspnea\\ on\\ exertion\\.\\ \\ significant\\ medical\\ history\\ included\\ a\\ positive\\ ppd\\ in\\ 1985\\ which\\ was\\ treated\\ with\\ 1\\ year\\ of\\ isoniazid\\.\\ \\ other\\ medical\\ history\\ included\\ hypertension\\ and\\ type\\ ii\\ diabetes\\ mellitus\\.\\ \\ she\\ had\\ immigrated\\ to\\ the\\ united\\ states\\ from\\ the\\ phillipines\\ two\\ decades\\ ago\\.\\ she\\ denied\\ any\\ history\\ of\\ smoking\\ or\\ alcohol\\ use\\.\\ \\ she\\ had\\ also\\ visited\\ the\\ philippines\\ several\\ months\\ ago\\.\ \(0\)\
\-\ the\\ presentation\\ of\\ this\\ patient\\ along\\ with\\ her\\ positive\\ cultures\\ solidifies\\ the\\ diagnosis\\ of\\ cryptococcal\\ pneumonia\\,\\ a\\ rare\\ condition\\ in\\ an\\ otherwise\\ healthy\\ female\\.\\ cryptococcus\\ neoformans\\ is\\ a\\ fungus\\ usually\\ acquired\\ via\\ inhalation\\ of\\ dehydrated\\ yeast\\ cells\\ or\\ basidiospores\\ that\\ has\\ been\\ shown\\ in\\ analysis\\ of\\ soils\\ to\\ be\\ found\\ with\\ pigeon\\ excreta\\.\\ inhalation\\ of\\ the\\ spores\\ is\\ believed\\ to\\ be\\ the\\ primary\\ means\\ of\\ acquisition\\.\\ \\ when\\ considering\\ the\\ prevalence\\ of\\ the\\ disease\\,\\ serologic\\ studies\\ have\\ demonstrated\\ evidence\\ of\\ widespread\\ subclinical\\ infection\\ in\\ individuals\\ without\\ a\\ history\\ of\\ symptomatic\\ infection\\ with\\ most\\ adults\\ having\\ a\\ positive\\ serum\\ antibody\\ to\\ cryptococcus\\ neoformans\\.\\ thus\\,\\ it\\ appears\\ that\\ the\\ subclinical\\ primary\\ infection\\ is\\ common\\ and\\ the\\ vast\\ majority\\ of\\ patients\\ are\\ asymptomatic\\.\\ \\ despite\\ strong\\ serologic\\ evidence\\,\\ symptomatic\\ cryptococcus\\ remains\\ a\\ very\\ rare\\ disease\\ in\\ individuals\\ without\\ impaired\\ immunity\\.\\ \\ an\\ active\\ surveillance\\ conducted\\ in\\ the\\ early\\ 90\\â\\€\\™s\\ in\\ alabama\\ estimated\\ the\\ incidence\\ of\\ active\\ cryptococcus\\ infections\\ at\\ 0\\.84\\ cases\\ per\\ 100\\,000\\ in\\ non\\-hiv\\ individuals\\.\\ \\ however\\,\\ in\\ patients\\ with\\ advanced\\ hiv\\ infections\\ living\\ in\\ san\\ francisco\\ and\\ atlanta\\ in\\ the\\ early\\ 90\\â\\€\\™s\\,\\ the\\ incidence\\ was\\ higher\\ and\\ was\\ estimated\\ to\\ be\\ anywhere\\ from\\ 17\\ to\\ 66\\ cases\\ per\\ 1000\\ individuals\\.\\ \\ other\\ patients\\ who\\ appear\\ to\\ be\\ at\\ increased\\ risk\\ include\\ cancer\\ patients\\ and\\ those\\ individuals\\ receiving\\ organ\\ transplants\\.\\ \\ thus\\,\\ the\\ subsequent\\ course\\ of\\ the\\ infection\\ \\(resolution\\ vs\\.\\ latent\\ infection\\ vs\\.\\ acute\\ infection\\ with\\ or\\ without\\ dissemination\\)\\ appears\\ to\\ be\\ primarily\\ determined\\ by\\ the\\ host\\â\\€\\™s\\ immune\\ status\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cryptococcus\\:\\ 0\\.05142043421592871\ \(0\)\
\-\ individuals\\:\\ 0\\.0380677635685298\ \(0\)\
\-\ cryptococcal\\:\\ 0\\.0372017003514804\ \(0\)\
\-\ neoformans\\:\\ 0\\.03534460825327506\ \(0\)\
\-\ \\-\\:\\ 0\\.030761851978308396\ \(0\)\
\-\ her\\:\\ 0\\.023536595344900175\ \(0\)\
\-\ infection\\:\\ 0\\.02275435029685014\ \(0\)\
\-\ serologic\\:\\ 0\\.02200329927185465\ \(0\)\
\-\ subclinical\\:\\ 0\\.021446592228208987\ \(0\)\
\-\ revealed\\:\\ 0\\.020934915189817504\ \(0\)\
\-\ inhalation\\:\\ 0\\.02020853082940543\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.01949638732553783\ \(0\)\
\-\ serum\\:\\ 0\\.018889330725514603\ \(0\)\
\-\ macrophages\\:\\ 0\\.018859423188858745\ \(0\)\
\-\ s\\:\\ 0\\.018708150130645702\ \(0\)\
\-\ eosinophils\\:\\ 0\\.01864875793241004\ \(0\)\
\-\ infections\\:\\ 0\\.018604251448214353\ \(0\)\
\-\ neutrophils\\:\\ 0\\.017479315940788342\ \(0\)\
\-\ conducted\\:\\ 0\\.017213632346926876\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.01685398948996082\ \(0\)\
\-\ malaise\\:\\ 0\\.01633521380508938\ \(0\)\
\-\ negative\\:\\ 0\\.015585466634350377\ \(0\)\
\-\ symptomatic\\:\\ 0\\.015549542403179599\ \(0\)\
\-\ estimated\\:\\ 0\\.015097152406285825\ \(0\)\
\-\ was\\:\\ 0\\.015088206446010485\ \(0\)\
\-\ rbc\\:\\ 0\\.015034192750704951\ \(0\)\
\-\ \\,\\:\\ 0\\.014878721158202055\ \(0\)\
\-\ hiv\\:\\ 0\\.01446711749636879\ \(0\)\
\-\ culture\\:\\ 0\\.013901797089847887\ \(0\)\
\-\ patients\\:\\ 0\\.013505799080097868\ \(0\)\
\-\ 386\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ 67\\.\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ 363\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ 586\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ fluconazol\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ paragonimus\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ westermani\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ immigrated\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ visited\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ philippines\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ solidifies\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ basidiospores\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ soils\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ pigeon\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ excreta\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ spores\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ 0\\.84\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ non\\-hiv\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ atlanta\\:\\ 0\\.013458806754147325\ \(0\)\
\-\ cultures\\:\\ 0\\.01342497043105313\ \(0\)\
\-\ thus\\:\\ 0\\.01298067246564477\ \(0\)\
\-\ positive\\:\\ 0\\.012700239344812748\ \(0\)\
\-\ 1\\:\\ 0\\.012417260262349355\ \(0\)\
\-\ bronchioaveolar\\:\\ 0\\.012400566783826799\ \(0\)\
\-\ 53\\-year\\-old\\:\\ 0\\.012400566783826799\ \(0\)\
\-\ phillipines\\:\\ 0\\.012400566783826799\ \(0\)\
\-\ alabama\\:\\ 0\\.012400566783826799\ \(0\)\
\-\ francisco\\:\\ 0\\.012400566783826799\ \(0\)\
\-\ 90\\:\\ 0\\.012299318110486878\ \(0\)\
\-\ without\\:\\ 0\\.012287103306004032\ \(0\)\
\-\ included\\:\\ 0\\.012031514811497241\ \(0\)\
\-\ incidence\\:\\ 0\\.011962377477910189\ \(0\)\
\-\ 199\\:\\ 0\\.01178153608442502\ \(0\)\
\-\ leiomyomatosis\\:\\ 0\\.01178153608442502\ \(0\)\
\-\ yeast\\:\\ 0\\.01178153608442502\ \(0\)\
\-\ immunity\\:\\ 0\\.01178153608442502\ \(0\)\
\-\ x\\-ray\\:\\ 0\\.011763889446432339\ \(0\)\
\-\ per\\:\\ 0\\.011420899568649378\ \(0\)\
\-\ count\\:\\ 0\\.011345502278297098\ \(0\)\
\-\ bacilli\\:\\ 0\\.01134232681350627\ \(0\)\
\-\ anca\\:\\ 0\\.01134232681350627\ \(0\)\
\-\ check\\-up\\:\\ 0\\.01134232681350627\ \(0\)\
\-\ metastasizing\\:\\ 0\\.01134232681350627\ \(0\)\
\-\ resolution\\:\\ 0\\.011253800638300534\ \(0\)\
\-\ ige\\:\\ 0\\.011001649635927325\ \(0\)\
\-\ isoniazid\\:\\ 0\\.011001649635927325\ \(0\)\
\-\ she\\:\\ 0\\.010986806754751935\ \(0\)\
\-\ nodules\\:\\ 0\\.010816851497412981\ \(0\)\
\-\ pneumonia\\:\\ 0\\.010785693725888579\ \(0\)\
\-\ smears\\:\\ 0\\.010723296114104493\ \(0\)\
\-\ else\\:\\ 0\\.0104879515647499\ \(0\)\
\-\ aerobic\\:\\ 0\\.0104879515647499\ \(0\)\
\-\ measles\\:\\ 0\\.0104879515647499\ \(0\)\
\-\ 1985\\:\\ 0\\.0104879515647499\ \(0\)\
\-\ latent\\:\\ 0\\.0104879515647499\ \(0\)\
\-\ 133\\:\\ 0\\.010284086843185743\ \(0\)\
\-\ transplants\\:\\ 0\\.010284086843185743\ \(0\)\
\-\ vs\\:\\ 0\\.010273221283666558\ \(0\)\
\-\ subsequent\\:\\ 0\\.010157498313923088\ \(0\)\
\-\ 24\\:\\ 0\\.010144906811071603\ \(0\)\
\-\ rare\\:\\ 0\\.010132367018849758\ \(0\)\
\-\ varicella\\:\\ 0\\.010104265414702714\ \(0\)\
\-\ dehydrated\\:\\ 0\\.010104265414702714\ \(0\)\
\-\ be\\:\\ 0\\.01005921162857961\ \(0\)\
\-\ cough\\:\\ 0\\.009997724820788007\ \(0\)\
\-\ active\\:\\ 0\\.009962011722274445\ \(0\)\
\-\ acquisition\\:\\ 0\\.009943409665606797\ \(0\)\
\-\ 100\\,000\\:\\ 0\\.009943409665606797\ \(0\)\
\-\ dissemination\\:\\ 0\\.009943409665606797\ \(0\)\
\-\ host\\:\\ 0\\.009943409665606797\ \(0\)\
\-\ ago\\:\\ 0\\.009712149071136636\ \(0\)\
\-\ appears\\:\\ 0\\.009712149071136636\ \(0\)\
\-\ begun\\:\\ 0\\.009542853536648795\ \(0\)\
\-\ cavitation\\:\\ 0\\.009542853536648795\ \(0\)\
\-\ san\\:\\ 0\\.009542853536648795\ \(0\)\
\-\ early\\:\\ 0\\.009542470136312787\ \(0\)\
\-\ wbc\\:\\ 0\\.009511678933055915\ \(0\)\
\-\ sao2\\:\\ 0\\.009429711594429372\ \(0\)\
\-\ lavage\\:\\ 0\\.009429711594429372\ \(0\)\
\-\ antigen\\:\\ 0\\.009429711594429372\ \(0\)\
\-\ 300\\:\\ 0\\.009429711594429372\ \(0\)\
\-\ papillomatosis\\:\\ 0\\.009429711594429372\ \(0\)\
\-\ 93\\:\\ 0\\.00932437896620502\ \(0\)\
\-\ hamartomas\\:\\ 0\\.00932437896620502\ \(0\)\
\-\ 1000\\:\\ 0\\.00932437896620502\ \(0\)\
\-\ fungus\\:\\ 0\\.009225846872865217\ \(0\)\
\-\ vast\\:\\ 0\\.009046025444382188\ \(0\)\
\-\ history\\:\\ 0\\.009009271280206742\ \(0\)\
\-\ benign\\:\\ 0\\.009004733945139546\ \(0\)\
\-\ resting\\:\\ 0\\.008963480068397036\ \(0\)\
\-\ quickly\\:\\ 0\\.008810680895027595\ \(0\)\
\-\ ambulation\\:\\ 0\\.008810680895027595\ \(0\)\
\-\ widespread\\:\\ 0\\.008739657970394171\ \(0\)\
\-\ cases\\:\\ 0\\.008692552256430938\ \(0\)\
\-\ antibody\\:\\ 0\\.008671792684026486\ \(0\)\
\-\ living\\:\\ 0\\.008671792684026486\ \(0\)\
\-\ anywhere\\:\\ 0\\.008671792684026486\ \(0\)\
\-\ immune\\:\\ 0\\.008671792684026486\ \(0\)\
\-\ disease\\:\\ 0\\.008529694908187507\ \(0\)\
\-\ ppd\\:\\ 0\\.008484613566328267\ \(0\)\
\-\ to\\:\\ 0\\.008476160930929498\ \(0\)\
\-\ revealing\\:\\ 0\\.00842699474498041\ \(0\)\
\-\ impaired\\:\\ 0\\.00842699474498041\ \(0\)\
\-\ decades\\:\\ 0\\.008371471624108846\ \(0\)\
\-\ wegener\\:\\ 0\\.008317897090045838\ \(0\)\
\-\ fast\\:\\ 0\\.008266138995884492\ \(0\)\
\-\ means\\:\\ 0\\.008266138995884492\ \(0\)\
\-\ mellitus\\:\\ 0\\.008216078197681453\ \(0\)\
\-\ 99\\:\\ 0\\.00816760690254469\ \(0\)\
\-\ ldh\\:\\ 0\\.00816760690254469\ \(0\)\
\-\ granulomatosis\\:\\ 0\\.00816760690254469\ \(0\)\
\-\ infiltrates\\:\\ 0\\.008120627270992394\ \(0\)\
\-\ surveillance\\:\\ 0\\.008120627270992394\ \(0\)\
\-\ examination\\:\\ 0\\.008111215375494855\ \(0\)\
\-\ parasitic\\:\\ 0\\.008075050228015782\ \(0\)\
\-\ united\\:\\ 0\\.008030794446529899\ \(0\)\
\-\ prevalence\\:\\ 0\\.008030794446529899\ \(0\)\
\-\ medical\\:\\ 0\\.008028426870430547\ \(0\)\
\-\ considering\\:\\ 0\\.007945954979117974\ \(0\)\
\-\ month\\:\\ 0\\.007827830658933159\ \(0\)\
\-\ 0\\:\\ 0\\.007826929724965744\ \(0\)\
\-\ believed\\:\\ 0\\.007826929724965744\ \(0\)\
\-\ gallops\\:\\ 0\\.0077892310797896035\ \(0\)\
\-\ dry\\:\\ 0\\.007752440924707068\ \(0\)\
\-\ primary\\:\\ 0\\.007729417596628081\ \(0\)\
\-\ in\\:\\ 0\\.007720254597989404\ \(0\)\
\-\ also\\:\\ 0\\.007715814932840388\ \(0\)\
\-\ demonstrated\\:\\ 0\\.007656244221242649\ \(0\)\
\-\ acid\\:\\ 0\\.007647108296482716\ \(0\)\
\-\ exertion\\:\\ 0\\.007647108296482716\ \(0\)\
\-\ organ\\:\\ 0\\.007647108296482716\ \(0\)\
\-\ strong\\:\\ 0\\.0075807188126052515\ \(0\)\
\-\ receiving\\:\\ 0\\.007548576203142913\ \(0\)\
\-\ rubs\\:\\ 0\\.007486252547386797\ \(0\)\
\-\ lobular\\:\\ 0\\.007368754774659884\ \(0\)\
\-\ abscesses\\:\\ 0\\.007368754774659884\ \(0\)\
\-\ mouth\\:\\ 0\\.0073407408224946975\ \(0\)\
\-\ mg\\:\\ 0\\.007157838227360926\ \(0\)\
\-\ months\\:\\ 0\\.0071265383043971516\ \(0\)\
\-\ 64\\:\\ 0\\.007109366932224161\ \(0\)\
\-\ emboli\\:\\ 0\\.007062387300671866\ \(0\)\
\-\ cell\\:\\ 0\\.007048063241470187\ \(0\)\
\-\ lobe\\:\\ 0\\.007020840757018425\ \(0\)\
\-\ murmurs\\:\\ 0\\.007016810257695254\ \(0\)\
\-\ 66\\:\\ 0\\.007016810257695254\ \(0\)\
\-\ acquired\\:\\ 0\\.006994522014304181\ \(0\)\
\-\ 41\\:\\ 0\\.006950898544923943\ \(0\)\
\-\ \\:\\:\\ 0\\.006902441624370473\ \(0\)\
\-\ bronchogenic\\:\\ 0\\.006887715008797447\ \(0\)\
\-\ septic\\:\\ 0\\.00684700012775598\ \(0\)\
\-\ primarily\\:\\ 0\\.00684700012775598\ \(0\)\
\-\ evidence\\:\\ 0\\.0068410460560820695\ \(0\)\
\-\ determined\\:\\ 0\\.006807342896605964\ \(0\)\
\-\ remains\\:\\ 0\\.006787894002289277\ \(0\)\
\-\ 33\\:\\ 0\\.006768689754645216\ \(0\)\
\-\ daily\\:\\ 0\\.006749724075258106\ \(0\)\
\-\ testicular\\:\\ 0\\.00669420095438654\ \(0\)\
\-\ advanced\\:\\ 0\\.006676133080116308\ \(0\)\
\-\ melanoma\\:\\ 0\\.006658276530859527\ \(0\)\
\-\ adults\\:\\ 0\\.006658276530859527\ \(0\)\
\-\ auscultation\\:\\ 0\\.006640626420323534\ \(0\)\
\-\ analysis\\:\\ 0\\.006640626420323534\ \(0\)\
\-\ smoking\\:\\ 0\\.006588868326162188\ \(0\)\
\-\ viral\\:\\ 0\\.006571998347251372\ \(0\)\
\-\ alcohol\\:\\ 0\\.006571998347251372\ \(0\)\
\-\ overall\\:\\ 0\\.006490336232822385\ \(0\)\
\-\ diabetes\\:\\ 0\\.006458856405031948\ \(0\)\
\-\ rounded\\:\\ 0\\.006428012577066269\ \(0\)\
\-\ majority\\:\\ 0\\.006412821232252273\ \(0\)\
\-\ higher\\:\\ 0\\.006397779558293476\ \(0\)\
\-\ denied\\:\\ 0\\.0063535237768075955\ \(0\)\
\-\ 17\\:\\ 0\\.0063535237768075955\ \(0\)\
\-\ fungal\\:\\ 0\\.006324716930541361\ \(0\)\
\-\ testing\\:\\ 0\\.006310514804339356\ \(0\)\
\-\ angiogram\\:\\ 0\\.006310514804339356\ \(0\)\
\-\ granulomatous\\:\\ 0\\.006296443575171534\ \(0\)\
\-\ chest\\:\\ 0\\.006243447328419904\ \(0\)\
\-\ fell\\:\\ 0\\.006241420771380393\ \(0\)\
\-\ nature\\:\\ 0\\.006175318777863867\ \(0\)\
\-\ markedly\\:\\ 0\\.006175318777863867\ \(0\)\
\-\ dyspnea\\:\\ 0\\.006175318777863867\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.0061624350089388834\ \(0\)\
\-\ states\\:\\ 0\\.006136989127282072\ \(0\)\
\-\ or\\:\\ 0\\.006116169459320351\ \(0\)\
\-\ \\%\\:\\ 0\\.0060864764376977335\ \(0\)\
\-\ despite\\:\\ 0\\.006063101278638026\ \(0\)\
\-\ a\\:\\ 0\\.006054958806390859\ \(0\)\
\-\ regular\\:\\ 0\\.0060157574057486205\ \(0\)\
\-\ other\\:\\ 0\\.006014163507488393\ \(0\)\
\-\ having\\:\\ 0\\.00599262487899961\ \(0\)\
\-\ ovarian\\:\\ 0\\.0059698376267604105\ \(0\)\
\-\ those\\:\\ 0\\.005936282043983655\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.005892658574603416\ \(0\)\
\-\ healthy\\:\\ 0\\.005881944723216169\ \(0\)\
\-\ lower\\:\\ 0\\.005868281127828588\ \(0\)\
\-\ sarcoma\\:\\ 0\\.005808981877664492\ \(0\)\
\-\ had\\:\\ 0\\.0056300757839410935\ \(0\)\
\-\ ii\\:\\ 0\\.005626900319150267\ \(0\)\
\-\ 2\\:\\ 0\\.005618639684001668\ \(0\)\
\-\ room\\:\\ 0\\.005608938728952424\ \(0\)\
\-\ infectious\\:\\ 0\\.005608938728952424\ \(0\)\
\-\ via\\:\\ 0\\.005600036560539\ \(0\)\
\-\ ed\\:\\ 0\\.005513758376930844\ \(0\)\
\-\ multiple\\:\\ 0\\.005495590850318378\ \(0\)\
\-\ nodular\\:\\ 0\\.005472381384903682\ \(0\)\
\-\ condition\\:\\ 0\\.0054561395555829855\ \(0\)\
\-\ neurologic\\:\\ 0\\.005448082979856507\ \(0\)\
\-\ 9\\:\\ 0\\.0053928468629442896\ \(0\)\
\-\ increasing\\:\\ 0\\.005347041900648413\ \(0\)\
\-\ appear\\:\\ 0\\.005339539587972949\ \(0\)\
\-\ cells\\:\\ 0\\.0052312163269465604\ \(0\)\
\-\ shown\\:\\ 0\\.0052312163269465604\ \(0\)\
\-\ use\\:\\ 0\\.0051563955954859585\ \(0\)\
\-\ hypertension\\:\\ 0\\.005143177179084257\ \(0\)\
\-\ cysts\\:\\ 0\\.005110623332566972\ \(0\)\
\-\ rate\\:\\ 0\\.005085070977825714\ \(0\)\
\-\ malignancy\\:\\ 0\\.005041358286719871\ \(0\)\
\-\ lungs\\:\\ 0\\.004940135264092024\ \(0\)\
\-\ course\\:\\ 0\\.0049229487686345665\ \(0\)\
\-\ studies\\:\\ 0\\.004872520485159022\ \(0\)\
\-\ which\\:\\ 0\\.004870670495397095\ \(0\)\
\-\ the\\:\\ 0\\.004854555035394494\ \(0\)\
\-\ clear\\:\\ 0\\.004823704752895642\ \(0\)\
\-\ breast\\:\\ 0\\.00481306556310008\ \(0\)\
\-\ reported\\:\\ 0\\.004755839466527957\ \(0\)\
\-\ very\\:\\ 0\\.004735550562529968\ \(0\)\
\-\ risk\\:\\ 0\\.0047255063318459335\ \(0\)\
\-\ including\\:\\ 0\\.0047105628106762195\ \(0\)\
\-\ later\\:\\ 0\\.0047105628106762195\ \(0\)\
\-\ otherwise\\:\\ 0\\.00468597745561274\ \(0\)\
\-\ status\\:\\ 0\\.004656988276613211\ \(0\)\
\-\ labs\\:\\ 0\\.00453736489608418\ \(0\)\
\-\ heart\\:\\ 0\\.004532946028868358\ \(0\)\
\-\ inflammatory\\:\\ 0\\.004524146479682479\ \(0\)\
\-\ that\\:\\ 0\\.004506811384912437\ \(0\)\
\-\ presentation\\:\\ 0\\.004493741426703943\ \(0\)\
\-\ on\\:\\ 0\\.004420708472460629\ \(0\)\
\-\ air\\:\\ 0\\.004414141414583154\ \(0\)\
\-\ masses\\:\\ 0\\.004410064729765018\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.004410064729765018\ \(0\)\
\-\ three\\:\\ 0\\.0043978995852624585\ \(0\)\
\-\ type\\:\\ 0\\.0043978995852624585\ \(0\)\
\-\ \\)\\:\\ 0\\.004357482089241558\ \(0\)\
\-\ by\\:\\ 0\\.004344643979373663\ \(0\)\
\-\ along\\:\\ 0\\.004311532636425215\ \(0\)\
\-\ cancer\\:\\ 0\\.004288801930327886\ \(0\)\
\-\ several\\:\\ 0\\.004194034863698301\ \(0\)\
\-\ 2\\.\\:\\ 0\\.004148769682137799\ \(0\)\
\-\ found\\:\\ 0\\.004111489487713149\ \(0\)\
\-\ any\\:\\ 0\\.0041081450886599905\ \(0\)\
\-\ enhancing\\:\\ 0\\.004091532111274441\ \(0\)\
\-\ some\\:\\ 0\\.003961722524987418\ \(0\)\
\-\ usually\\:\\ 0\\.003961722524987418\ \(0\)\
\-\ patient\\:\\ 0\\.00392332182099109\ \(0\)\
\-\ renal\\:\\ 0\\.003919809999172625\ \(0\)\
\-\ treated\\:\\ 0\\.003905115780280701\ \(0\)\
\-\ 6\\:\\ 0\\.0038963666585875942\ \(0\)\
\-\ decreased\\:\\ 0\\.0038790174087397853\ \(0\)\
\-\ from\\:\\ 0\\.003866979276806755\ \(0\)\
\-\ pulmonary\\:\\ 0\\.0038115271911756694\ \(0\)\
\-\ two\\:\\ 0\\.003736383568879398\ \(0\)\
\-\ when\\:\\ 0\\.003736383568879398\ \(0\)\
\-\ lymphoma\\:\\ 0\\.003728547533419062\ \(0\)\
\-\ fluid\\:\\ 0\\.0037078459612272566\ \(0\)\
\-\ following\\:\\ 0\\.003702714132673509\ \(0\)\
\-\ all\\:\\ 0\\.003689959525849299\ \(0\)\
\-\ chronic\\:\\ 0\\.0036747933326824428\ \(0\)\
\-\ include\\:\\ 0\\.0036597763176034913\ \(0\)\
\-\ ct\\:\\ 0\\.003649782147761963\ \(0\)\
\-\ however\\:\\ 0\\.0036326229856443824\ \(0\)\
\-\ an\\:\\ 0\\.003608136990182381\ \(0\)\
\-\ and\\:\\ 0\\.0035726978236928853\ \(0\)\
\-\ been\\:\\ 0\\.003549305174754185\ \(0\)\
\-\ at\\:\\ 0\\.003535154665134757\ \(0\)\
\-\ significant\\:\\ 0\\.003508163589395761\ \(0\)\
\-\ due\\:\\ 0\\.0034813391648134957\ \(0\)\
\-\ common\\:\\ 0\\.003414148415200606\ \(0\)\
\-\ who\\:\\ 0\\.0034014784872392397\ \(0\)\
\-\ both\\:\\ 0\\.0033316030392154523\ \(0\)\
\-\ metastatic\\:\\ 0\\.0032841364940703666\ \(0\)\
\-\ acute\\:\\ 0\\.003221189815429764\ \(0\)\
\-\ increased\\:\\ 0\\.003191579819541459\ \(0\)\
\-\ imaging\\:\\ 0\\.003056601258710844\ \(0\)\
\-\ 3\\:\\ 0\\.003054924468254259\ \(0\)\
\-\ of\\:\\ 0\\.003023762768802753\ \(0\)\
\-\ woman\\:\\ 0\\.003013592286242605\ \(0\)\
\-\ most\\:\\ 0\\.0030119620484398107\ \(0\)\
\-\ diagnosis\\:\\ 0\\.002995754703481557\ \(0\)\
\-\ were\\:\\ 0\\.0029622692163204906\ \(0\)\
\-\ it\\:\\ 0\\.0029325929534855214\ \(0\)\
\-\ left\\:\\ 0\\.002919405402360045\ \(0\)\
\-\ have\\:\\ 0\\.0028250963028474685\ \(0\)\
\-\ female\\:\\ 0\\.002682076750302036\ \(0\)\
\-\ presents\\:\\ 0\\.0026651057946685893\ \(0\)\
\-\ treatment\\:\\ 0\\.002640636579543339\ \(0\)\
\-\ is\\:\\ 0\\.0025753776109224075\ \(0\)\
\-\ has\\:\\ 0\\.0024499236190752335\ \(0\)\
\-\ normal\\:\\ 0\\.0020452098543497724\ \(0\)\
\-\ with\\:\\ 0\\.0017863232990822859\ \(0\)\
\-\ are\\:\\ 0\\.0017784333931749644\ \(0\)\
\-\ \\.\\:\\ 0\\.0016801307160576099\ \(0\)\
\-\ this\\:\\ 0\\.0014673850584948597\ \(0\)\
\-\ year\\:\\ 0\\.0014597027011800225\ \(0\)\
\-\ for\\:\\ 0\\.0011131422116682672\ \(0\)\
\-\ \\(\\:\\ 0\\.0011028423301432985\ \(0\)\
